Seres Therapeutics

Seres Therapeutics company information, Employees & Contact Information

Explore related pages

Seres Therapeutics email format Seres Therapeutics management contacts

Related company profiles:

Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit http://www.serestherapeutics.com/ .

Company Details

Employees
172
Founded
-
Address
101 Cambridgepark Dr, Cambridge,massachusetts 02140,united States
Phone
617-945-9626
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
serestherapeutics.com
Keywords
Biotechnology, Therapeutics, Microbiome.
HQ
Cambridge, Massachusetts
Competitors
Tessera Therapeutics, Finch Therapeutics, Spero Therapeutics, Intellia Therapeutics, Inc., Kaleido Biosciences, Sage Therapeutics, Vedanta Biosciences, Inc., Vertex Pharmaceuticals, Sarepta Therapeutics, Beam Therapeutics.
Looking for a particular Seres Therapeutics employee's phone or email?

Seres Therapeutics Questions

News

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant - Yahoo Finance

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant Yahoo Finance

Seres Therapeutics Presents 77% BSI Reduction in SER-155 Phase 1b | MCRB Stock News - Stock Titan

Seres Therapeutics Presents 77% BSI Reduction in SER-155 Phase 1b | MCRB Stock News Stock Titan

Seres Therapeutics to Host Conference Call on August 6, 2025, to Discuss Q2 Financial Results and Business Updates - Quiver Quantitative

Seres Therapeutics to Host Conference Call on August 6, 2025, to Discuss Q2 Financial Results and Business Updates Quiver Quantitative

Seres Therapeutics Receives FDA Feedback Supporting SER-155 Study Plans for Bloodstream Infection Reduction in Allogeneic Hematopoietic Stem Cell Transplant Patients - Nasdaq

Seres Therapeutics Receives FDA Feedback Supporting SER-155 Study Plans for Bloodstream Infection Reduction in Allogeneic Hematopoietic Stem Cell Transplant Patients Nasdaq

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates Yahoo Finance

Mark Your Calendar: Leading Biotherapeutics Company Seres Therapeutics Announces Q2 2025 Earnings Date - Stock Titan

Mark Your Calendar: Leading Biotherapeutics Company Seres Therapeutics Announces Q2 2025 Earnings Date Stock Titan

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 - The Manila Times

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 The Manila Times

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway - Yahoo Finance

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway Yahoo Finance

Seres Therapeutics Receives $50 Million Payment from Nestlé Health Science Following VOWST Business Sale - Nasdaq

Seres Therapeutics Receives $50 Million Payment from Nestlé Health Science Following VOWST Business Sale Nasdaq

Seres shrinks head count by 25% to fund phase 2 study of infection biotherapeutic - Fierce Biotech

Seres shrinks head count by 25% to fund phase 2 study of infection biotherapeutic Fierce Biotech

Live Biotherapeutics Leader Seres Therapeutics to Present Company Overview at H.C. Wainwright Conference - Stock Titan

Live Biotherapeutics Leader Seres Therapeutics to Present Company Overview at H.C. Wainwright Conference Stock Titan

Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough - Seeking Alpha

Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough Seeking Alpha

Seres Therapeutics Announces Leadership Transition - Yahoo Finance

Seres Therapeutics Announces Leadership Transition Yahoo Finance

Seres Therapeutics’ Strategic Sale Of VOWST Warrants A Rating Upgrade (MCRB) - Seeking Alpha

Seres Therapeutics’ Strategic Sale Of VOWST Warrants A Rating Upgrade (MCRB) Seeking Alpha

Seres Therapeutics Receives $50M Payment from Nestlé, Extends Cash Runway to 2026 - Stock Titan

Seres Therapeutics Receives $50M Payment from Nestlé, Extends Cash Runway to 2026 Stock Titan

Seres Therapeutics to Present Company Overview at H.C. Wainwright Global Investment Conference on September 8, 2025 | MCRB Stock News - Quiver Quantitative

Seres Therapeutics to Present Company Overview at H.C. Wainwright Global Investment Conference on September 8, 2025 | MCRB Stock News Quiver Quantitative

Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection - Business Wire

Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection Business Wire

Seres Therapeutics jumps on report of Nestle acquisition offer - Seeking Alpha

Seres Therapeutics jumps on report of Nestle acquisition offer Seeking Alpha

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - ADVFN

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates ADVFN

Microbiome momentum: Exploring human health at the core - statnews.com

Microbiome momentum: Exploring human health at the core statnews.com

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI - Business Wire

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI Business Wire

Reducing Recurrent Clostridioides difficile Infection Risk With Oral Microbiome Therapy - Gastroenterology Advisor

Reducing Recurrent Clostridioides difficile Infection Risk With Oral Microbiome Therapy Gastroenterology Advisor

Seres Therapeutics Appoints Claire M. Fraser, Ph.D., to its Board of Directors - citybiz

Seres Therapeutics Appoints Claire M. Fraser, Ph.D., to its Board of Directors citybiz

Microbiome Therapeutics Market Size to Hit USD 3,405.99 Million by 2034 - Precedence Research

Microbiome Therapeutics Market Size to Hit USD 3,405.99 Million by 2034 Precedence Research

Seres Therapeutics soars on report of takeover offer (MCRB:NASDAQ) - Seeking Alpha

Seres Therapeutics soars on report of takeover offer (MCRB:NASDAQ) Seeking Alpha

Vowst Approved to Prevent Recurrent C. difficile Infection - MPR - Medical Professionals Reference

Vowst Approved to Prevent Recurrent C. difficile Infection - MPR Medical Professionals Reference

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection - The New England Journal of Medicine

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection The New England Journal of Medicine

Microbiota therapeutics for inflammatory bowel disease: the way forward - The Lancet

Microbiota therapeutics for inflammatory bowel disease: the way forward The Lancet

Emerging Trends in “Smart Probiotics”: Functional Consideration for the Development of Novel Health and Industrial Applications - Frontiers

Emerging Trends in “Smart Probiotics”: Functional Consideration for the Development of Novel Health and Industrial Applications Frontiers

Seres shares crash after microbiome drug flunks PhII - Fierce Biotech

Seres shares crash after microbiome drug flunks PhII Fierce Biotech

Companies like Seres Therapeutics

Vedanta Biosciences, Inc. logo - Similar company to Seres Therapeutics

Vedanta Biosciences,...

138
Tessera Therapeutics logo - Similar company to Seres Therapeutics

Tessera Therapeutics

326
Intellia Therapeutics, Inc. logo - Similar company to Seres Therapeutics

Intellia Therapeutic...

446
Sarepta Therapeutics logo - Similar company to Seres Therapeutics

Sarepta Therapeutics

1.37K
Finch Therapeutics logo - Similar company to Seres Therapeutics

Finch Therapeutics

15
Vertex Pharmaceuticals logo - Similar company to Seres Therapeutics

Vertex Pharmaceuticals

6.09K
Spero Therapeutics logo - Similar company to Seres Therapeutics

Spero Therapeutics

47
Beam Therapeutics logo - Similar company to Seres Therapeutics

Beam Therapeutics

557
Kaleido Biosciences logo - Similar company to Seres Therapeutics

Kaleido Biosciences

9
Sage Therapeutics logo - Similar company to Seres Therapeutics

Sage Therapeutics

451

Top Seres Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant